Meltzer Herbert Y, Rajagopal Lakshmi, Matrisciano Francesco, Hao Junliang, Svensson Kjell A, Huang Mei
Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.
Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.
Behav Brain Res. 2019 Apr 1;361:139-150. doi: 10.1016/j.bbr.2018.12.006. Epub 2018 Dec 3.
Diminished dopamine D1 stimulation may contribute to cognitive impairment in Alzheimer's and Parkinson's diseases, schizophrenia, and other neuropsychiatric disorders. However, orthosteric D1 receptor (D1R) agonists produce receptor desensitization and an inverted U-shaped dose-response curve, but positive allosteric modulators (PAMs) do not. We examined the cognitive effects of DETQ, a D1R PAM, in mice genetically modified to express the human D1 receptor ("hD1 mice"). Phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate receptor antagonist, dosed seven days (subchronic), followed by withdrawal, produced a prolonged deficit in novel object recognition (NOR) memory, which was reversed by acute treatment with DETQ, with no evidence for an inverted U-shaped response. This was blocked by the D1R antagonist, SCH391660. Single doses of D1R agonists, SKF38393 and SKF82958, and the acetylcholinesterase inhibitor, rivastigmine, alone and the combination of subeffective doses of both DETQ and rivastigmine, also restored NOR in both subchronic PCP-treated in hD1 mice. DETQ increased cortical and hippocampal acetylcholine efflux after both acute and subchronic dosing in hD1 mice. Subchronic but not acute DETQ, inhibited glutamate and GABA efflux. DETQ-induced acetylcholine efflux was absent in subchronic PCP-treated mice, indicating that restoration of NOR in subchronic PCP-treated mice does not require cortical acetylcholine efflux. This is additional evidence that DETQ stimulates D1R without producing an inverted-U-shaped response curve and increases neurotransmitter release in the mPFC and HIP without causing tolerance. The ability of D1 PAMs to improve cognition in humans with neuropsychiatric disorders without evidence of tolerance or an inverted-U-shaped response curve needs to be established clinically.
多巴胺D1刺激减弱可能导致阿尔茨海默病、帕金森病、精神分裂症和其他神经精神疾病中的认知障碍。然而,正构D1受体(D1R)激动剂会导致受体脱敏和倒U形剂量反应曲线,而正变构调节剂(PAM)则不会。我们研究了D1R PAM DETQ对经基因改造以表达人D1受体的小鼠(“hD1小鼠”)的认知影响。苯环己哌啶(PCP)是一种非竞争性N-甲基-D-天冬氨酸受体拮抗剂,给药7天(亚慢性),然后停药,会导致新物体识别(NOR)记忆长期受损,急性给予DETQ可逆转这种损伤,且没有倒U形反应的证据。这被D1R拮抗剂SCH391660阻断。单剂量的D1R激动剂SKF38393和SKF82958、乙酰胆碱酯酶抑制剂卡巴拉汀单独使用以及DETQ和卡巴拉汀的亚有效剂量联合使用,也能恢复hD1小鼠亚慢性PCP处理后的NOR。急性和亚慢性给药后,DETQ均增加了hD1小鼠皮质和海马中的乙酰胆碱外流。亚慢性而非急性的DETQ抑制了谷氨酸和GABA外流。亚慢性PCP处理的小鼠中不存在DETQ诱导的乙酰胆碱外流,这表明亚慢性PCP处理的小鼠中NOR的恢复不需要皮质乙酰胆碱外流。这是额外的证据,表明DETQ刺激D1R而不产生倒U形反应曲线,并增加内侧前额叶皮质(mPFC)和海马(HIP)中的神经递质释放而不产生耐受性。D1 PAM在神经精神疾病患者中改善认知而无耐受性或倒U形反应曲线证据的能力需要在临床上得到证实。